Seventure Partners Release: Health For Life Capital Further Expands Israeli Portfolio With Investment In Microbiome App Developer

Paris, France – 27 June 2017 - Seventure Partners, one of Europe’s leaders in financing innovation, and a world-leader in the venture investment in the microbiome sector, today announces that it has invested in Israel-based personalized nutrition microbiome app company DayTwo through its Health for Life Capital™ investment vehicle, as part of a $12m series A fundraising.

DayTwo offers personalized nutrition recommendations using machine-learning predictive algorithms which integrate data from the gut microbiome to produce clinical readouts to provide actionable insights for maintaining health through the control of blood glucose levels and its maintenance within healthy narrow range. Based on the DNA sequence of the individual’s gut microbiome, DayTwo prepares a uniquely detailed gut analysis report for each individual, which is then used to deliver tailored nutritional recommendations via an app on the user’s smart device. DayTwo’s technology platform is based on research conducted by Professor Eran Segal and by Dr. Eran Elinav both from the Weizmann Institute of Science in Israel, which has been exclusively licensed to DayTwo for those applications.

The investment by Seventure Partners was in syndication with Johnson & Johnson as well as historical investors and will be used by DayTwo to commercialise its product internationally beyond Israel and develop new products tailored for other user segments. The first stage of commercialisation will target highly-motivated consumers, giving them insight into how to manage the food choices that are best for them. DayTwo announced in February that it had joined forces with J&J to develop personalised microbiome analysis for diabetes nutrition.

Seventure Partners recently announced that its Health for Life Capital™ investment vehicle had invested in Israel for the first time, joining a syndicate of investors to fund Biomx, a leading developer of bacteriophage-based therapies for the treatment and prevention of diseases stemming from dysbiosis of the microbiome.

Eric de La Fortelle, Venture Partner at Seventure Partners, based in Basel, said “The field of nutrition advice largely relies on general recipes based questionable heuristics. DayTwo brings a strong scientific grounding to this advice, and makes it personal by connecting it directly to each individual’s gut physiology.”

Isabelle de Cremoux, CEO and Managing Partner of Seventure Partners and founder of Health for Life Capital™, said: “DayTwo is a great example of how technology and life sciences can intersect, in the fast growing area of healthcare IT is now expanding into the microbiome and personalised nutrition space. DayTwo brings the latest progress of microbiome science to users’ fingertips. Its proprietary analysis of stool samples is turned into actionable nutrition advice to manage their well-being and health. DayTwo is a pioneer in translating this new science for the benefit of millions. “

“DayTwo rounds out our microbiome portfolio that already includes Enterome (microbiome modulator drugs, diagnostics and companion diagnostics), LNC (drug-probiotic and nutrition microbiome-modulator products), Maat Pharma (autologous microbiome transplant), TargEDys (bacteria for regulation of appetite) and Eligo Bioscience (phage-delivered highly-specific antibiotics), BiomX (bacteriophage-based therapies) and Vedanta (drug-probiotic). We anticipate making additional investments from the Health for Life Capital ™ in the coming months.”

- ENDS -

Notes To Editors

About Seventure Partners

With over €660m in assets under management as of the end of 2016, Seventure Partners is a leading venture capital firm in Europe. Since 1997, Seventure Partners has invested in innovative businesses with high growth potential in two fields: Digital technologies in France and Germany, and Life sciences across Europe, Israel and North America. In Life sciences, the four areas of focus include biotechnology and pharmaceuticals, connected health and medtech, industrial biotechnology, and last but not least: the MICROBIOME, nutrition, foodtech and personalized medicine. Investments can range between €500k and €10m per round, or up to €20m per company, from early to late stage. Recently, Seventure Partners successfully launched Health for Life Capital™ which has attracted strategic investments from prestigious organizations including Danone, Tereos, Tornier, Lesaffre, Bel and Novartis, as well as entrepreneurs and financial institutions.

For more details: Twitter @SeventureP

About Health For Life Capital™

Seventure Partners launched Health for Life Capital™, the first venture capital fund focused mainly on investments in the microbiome and nutrition space. Europe is the primary focus of the fund, but it also invests in North America, Israel and Asia. The €160m fund attracted strategic investments from prestigious organisations including Danone, Novartis, Tereos, Tornier, Lesaffre and Bel, as well as financial institutions and entrepreneurs. Health for Life Capital™ is managed by Seventure’s Life sciences team.

For more details:

Back to news